07 Oct 2026
Transmission of Annual Report for the Year Ended 30 June 2026 Citi Pharma Limited transmitted its Annual Financial Statements for the year ended June 30, 2026, to the Pakistan Stock Exchange. Financials 07 Oct 2026
Notice of Annual General Meeting - Post Publication Citi Pharma Limited published the notice of its Annual General Meeting scheduled for October 28, 2026, to consider financial statements, auditor appointments, and confirming the EGM minutes, while announcing no dividend for the year ended June 30, 2026. Meetings 06 Oct 2026
Notice of Annual General Meeting (Prior to Publication) Citi Pharma Limited has issued a notice for its upcoming Annual General Meeting (AGM) scheduled for October 28, 2026, to review financial statements and appoint auditors. The Board of Directors has recommended no dividend for the year ended June 30, 2026. Share transfer books will remain closed from October 22 to October 28, 2026. Meetings 05 Oct 2026
Financial Results for the Year Ended 30 June 2026 Citi Pharma Limited reported its annual financial results for the year ended June 30, 2026, showing a consolidated net profit after tax of PKR 790.33 million compared to PKR 892.04 million in the prior year, alongside a basic earnings per share of PKR 3.46. Standalone profit after tax stood at PKR 782.60 million compared to PKR 892.04 million previously. Financials 28 Sep 2026
Board Meeting Citi Pharma Limited has announced a meeting of its Board of Directors scheduled for October 03, 2026, to consider the Annual Audited Financial Statements for the year ended June 30, 2026. A closed period has been declared from September 27, 2026, to October 03, 2026. Meetings 18 Sep 2026
Certified Copy of the Resolutions Adopted in the Extraordinary General Meeting held on 18 September 2026 Citi Pharma Limited published the certified copy of resolutions adopted at its Extraordinary General Meeting (EGM) held on September 18, 2026. Shareholders approved the alteration of the Memorandum of Association to enable the company to undertake cannabis, industrial hemp, and related medical/allied activities subject to regulatory approvals. Meetings 28 Aug 2026
Notice of Extraordinary General Meeting Citi Pharma Limited has issued a notice for its Extraordinary General Meeting (EOGM) scheduled for September 18, 2026, to consider a special resolution altering the Memorandum of Association. The alteration involves adding Clause No. 38 to expand the company's business activities into the full spectrum of cannabis-related, industrial hemp, medicinal cannabis, and marijuana operations, following receipt of an NOC from the Cannabis Control and Regulatory Authority (CCRA). Meetings 10 Aug 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations Citi Pharma Limited disclosed a share purchase transaction by its Executive Director, Rizwan Ahmad, involving 2,000,000 shares bought at a rate of 74.66 on August 5, 2026, under PSX Regulation 5.6.4. Insiders 07 Aug 2026
Chief Financial Officer Citi Pharma Limited announced the resignation of its Chief Financial Officer, Mr. Salman Anwar Malik, effective August 07, 2026. The acting charge of the office of CFO has been assigned to Mr. Hanan Alam, the current Financial Controller. Material 09 Jul 2026
Certified Copy of the Resolutions Adopted in the Extraordinary General Meeting held on 08 July 2026 OTHERS 09 Jul 2026
Minutes of Extraordinary General Meeting REVOKED OTHERS 08 Jul 2026
Material Information OTHERS 01 Jul 2026
Board Meeting Other Than Financial Results Citi Pharma Limited has scheduled a Board of Directors meeting for July 8, 2026, to consider and approve a proposed Scheme of Arrangement and demerger involving the company and Citi Core Holdings (Private) Limited. Meetings 15 Jun 2026
Notice of Extraordinary General Meeting OTHERS 21 May 2026
Material Information OTHERS 06 May 2026
Material Information OTHERS 30 Apr 2026
Transmission of Quarterly Report for the Period Ended 31st March 2026 Financials 30 Apr 2026
Financial Results for the Quarter Ended 31 March 2026 Financials 27 Apr 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations OTHERS 27 Apr 2026
Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations Rizwan Ahmad, an Executive Director of Citi Pharma Limited, purchased 100,000 shares of the company at a rate of 79.77 per share on April 23, 2026. Insiders 
